Hemin

DRUG3 trials

Sponsors

Mayo Clinic, Erasme University Hospital, The University of Texas Medical Branch, Galveston

Conditions

Acute Intermittent PorphyriaDiabetes MellitusGastroparesisHereditary CoproporphyriaPost-ERCP Acute PancreatitisVariegate Porphyria

Phase 2

A Pilot Study of Hemin Therapy for Gastroparesis (Diabetes Mellitus)

CompletedNCT01206582

Mayo ClinicDiabetes Mellitus, Gastroparesis

Start: 2010-05-31End: 2014-12-31Updated: 2016-02-04

Hemin to Prevent Post-ERCP (Endoscopic Retrograde Cholangiopancreatography) Acute Pancreatitis

CompletedNCT01855841

Erasme University HospitalPost-ERCP Acute Pancreatitis

Start: 2012-04-30End: 2021-06-30Updated: 2021-07-07

Unknown Phase

Acute Porphyria Biomarkers for Disease Activity

Active, not recruitingNCT02935400

The University of Texas Medical Branch, GalvestonAcute Intermittent Porphyria, Hereditary Coproporphyria, Variegate Porphyria

Start: 2014-04-28End: 2026-12-31Target: 50Updated: 2026-05-12

Related Papers

Intravenous Hemin, a potential heme oxygenase-1 activator, does not protect from post-ERCP acute pancreatitis in humans: Results of a randomized multicentric multinational placebo-controlled trial.

2024-02-152 citations